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We have mapped the binding sites on human papillomavirus (HPV) type 6 for three HPV 6-specific neutralizing monoclonal
antibodies (mAbs). The critical binding residues were first identified by making HPV 11-like amino acid substitutions in the
HPV 6 major capsid protein L1 and assaying the resulting virus-like particles (VLPs) for reactivity with the mAbs. To confirm
the relevance of these residues for mAb binding, we demonstrated that HPV 6 type-specificity could be transferred to HPV
11 VLPs by making the appropriate HPV 6-like amino acid substitutions in the HPV 11 L1. Two binding regions were found.
For one mAb, all critical residues are centered at residue 53, while for the other two mAbs, type-specific binding also requires
a second site located more than 100 residues distal to the first. Both binding sites coincide with regions of L1 where the
sequences of the closely related HPV 6 and 11 diverge. These regions are where the L1 sequences are the least well
conserved among all HPV types and they have been implicated in type-specific binding for other HPV types. This suggests
that clusters of diverged residues, surrounded by conserved L1 sequences, are presented on the surface of assembled
particles and are responsible for eliciting critical humoral immune responses to the virus. © 2001 Academic Press
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Human papillomavirus (HPV) infection has been linked
to both benign and malignant lesions of the cutaneous,
genital, and respiratory epithelia (reviewed in Shah and
Howley, 1996). Of the approximately 100 genotypes de-
scribed to date, 2 closely related types, HPV 6 and HPV
11, are etiological agents for approximately 90% of the
observed cases of anogenital warts (condylomata
acuminata) (Galloway, 1994; Gissmann et al., 1983). In-
fection with these types is widespread; annually, about
1% of the U.S. population between the ages of 15 and 50
are diagnosed with condyloma (Koutsky et al., 1988). For
this reason, vaccines that would prevent the spread of
infection of HPV 6 and HPV 11 are highly desirable. A
promising approach to HPV vaccine development has
employed virus-like particles (VLPs). These particles are
morphologically and immunologically similar to native
virions and assemble spontaneously when the HPV ma-
jor capsid protein L1 is expressed recombinantly in eu-
karyotic cells (Christensen et al., 1994; Hagensee et al.,
1993; Hofmann et al., 1995; Kirnbauer et al., 1992; Lowe et
al., 1997; Rose et al., 1993). In bovine, canine, and rabbit
disease models, immunization with VLPs has provided1 To whom correspondence and reprint requests should be ad-
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262protection against infection (Breitburd et al., 1995; Chris-
tensen et al., 1994; Jansen et al., 1995; Kirnbauer et al.,
1996; Suzich et al., 1995). Currently several VLP-based
vaccines are under evaluation in human clinical trials.
To monitor seroconversion in the patient population
following either vaccination or natural infection, it is nec-
essary to have reagents that can distinguish relevant
type-specific responses. Ideally, these include monoclo-
nal antibodies (mAbs) that recognize neutralizing
epitopes. For HPV 11, where neutralization assays have
been long established, a number of type-specific, con-
formation-dependent, neutralizing mAbs have been de-
scribed (Christensen and Kreider, 1990; Christensen et
al., 1990; Ludmerer et al., 1996, 1997, 2000). To identify
similar tools for HPV 6, we evaluated several members of
a panel of mAbs raised against HPV 6 VLPs (Christensen
et al., 1996b). Although many of the mAbs are cross-
reactive with closely related HPV 11 VLPs [the L1 se-
quences of the two types are .92% identical in amino
acid sequence (Swiss-Prot Accession Nos. P03100 and
P04012)], three conformation-dependent, HPV 6-specific
mAbs were identified: H6.B10.5, H6.M48, and H6.N8
(Christensen et al., 1996b). Recently all three mAbs were
shown to neutralize HPV 6 in a pseudovirion neutraliza-
tion assay (Yeager et al., 2000). In this work, we describe
the mapping of the binding sites in L1 for these neutral-
izing mAbs.
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263NEUTRALIZING EPITOPES OF HPV 6RESULTS
dentification of amino acid residues in HPV 6 L1
ritical for mAb binding: Mutation of HPV 6 L1
esidues 49 and 53 abrogates binding of HPV
-specific monoclonal antibodies
To identify residues in HPV 6 L1 that are critical for
Ab binding, we generated HPV 6 L1 mutants bearing
PV 11-like amino acid substitutions and looked for loss
f binding to the mAbs. We focused on regions where the
PV 6 and 11 L1 proteins show the greatest divergence
f sequence (Fig. 1, Table 1). Analysis of the hydropath-
city of L1 indicated that some of these diverged regions
FIG. 1. Comparison of HPV 6 and 11 L1 amino acid sequences. The c
Positions where the sequence differs are indicated with the HPV 6 an
respectively. Residues critical to this study are indicated in boldface tyre hydrophilic and are therefore likely to be surface-
xposed (data not shown). We reasoned that type-spe-
a
V
170–179
b
H
c
pific responses that discriminate between the closely
elated 6 and 11 L1 sequences are likely to target diver-
ent, surface-exposed regions. Because the carboxyl-
erminus is not critical for VLP formation (Paintsil et al.,
996), this divergent region was excluded from the scan.
LPs, produced from prototype or mutant L1 genes, were
nalyzed for reactivity with the monoclonals in an ELISA
sing saturating levels of antibody. The results of this
urvey, summarized in Table 2, indicated that the region
ncompassing residues 49 and 53 was critical for bind-
ng all three mAbs. VLPs produced from the F49Y, R53K
ouble mutant (HPV6:49, 53) are not recognized by any of
he 6-specific mAbs. The loss of binding is not due to the
ailure of the mutant VLPs to assemble since H6.J54,
us linear amino acid sequence for HPV 6 and 11 L1 proteins is shown.
PV 11 residues indicated above and below the consensus sequence,nother conformation-dependent mAb, binds the mutant
LPs as well as it does prototype HPV 6 VLPs.TABLE 1
Amino Acid Substitutions in HPV 6 and 11 Mutant L1 Proteins
Mutant Amino acid substitutions
H6:49, 53 F49Y, R53K
H6:28 T28K
H6:169–178 K169T, T172S, P175S, A178N
H6:262–289 E262T, T270D, S276G, G277N, T280S, G283A, N289H
H6:324 Q324H
H6:345–348 T345S, T346K, S348A
H6:433, 438 P433Q, N438D
H11:28 K28T
H11:49 Y49F
H11:53 K53R
H11:103 K53R, M363V
H11:54 V54A
H11:49, 53 Y49F, K53R
H11:49–54 Y49F, K53R, V54A
H11:170–179 T170K, S173T, S175P, N179A
H11:49–54, Y49F, K53R, V54A, T170K, S173T, S175P, N179ATABLE 2
Relative Binding Activitya
VLP
mAb
H6.B10.5 H6.M48 H6.N8 H6.J54
HPV 6 1.3 1.1 1.4 1.3
HPV6:28 1.1 1.4 3.1 1.2
HPV6:49, 54 0.0 0.0 0.0 1.3
HPV6:169–178 0.7 0.6 1.3 1.8
HPV6:262–289 1.3 1.1 1.3 1.6
HPV6:324 1.1 1.1 n.d.b 1.7
HPV6:345–348 1.6 1.3 1.3 1.7
HPV6:433, 438 1.9 1.5 1.9 1.2
HPV 11 ,0.1 0.1 0.2 1.5
a Relative binding activity of each antibody–VLP pair was calculated
y normalizing the A 450 signal for that pair to that generated with mAb
6.C6 in the same assay. H6.C6 binds a linear surface epitope that is
ommon to both HPV 6 and HPV 11 L1 and thus measures the total L1onsensroduced.
b n.d., not determined.
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264 MCCLEMENTS ET AL.The region defined by amino acid residues 49–54 is
critical for HPV 6-specific, conformation-dependent
antibody recognition
To confirm the role of residues 49–54 in mAb binding,
and to characterize the HPV 6 binding sites further, we
evaluated the transfer of HPV 6-specific binding to HPV
11 VLPs by making HPV 6-like amino acid substitutions
in HPV 11 L1, focusing our initial efforts on the amino-
terminal region of divergence defined by residues 49, 53,
and 54 since mutations in that region had the greatest
impact on binding to the HPV 6-specific mAbs.
HPV 11 VLPs bearing single, double, or triple HPV
6-like substitutions (Table 1) were assayed for mAb bind-
ing (Fig. 2). The mutant H11:53, which has an arginine for
lysine substitution at position 53, showed nearly quanti-
tative transfer of H6.N8 binding to the HPV 11 L1 back-
ground. In contrast, the doubly (H11:49, 53; Y49F, K53R)
and triply (H11:49–54; Y49F, K53R, V54A) substituted HPV
11 VLPs, while also showing quantitative transfer of
H6.N8 binding, showed only partial reactivity with H6.B10
and H6.M48. This suggests differences in binding spec-
ificities among the antibodies, as has previously been
observed with other HPV type-specific mAbs (Ludmerer
et al., 1997). Whereas the type-specificity of H6.N8 ap-
pears focused on position 53, the transfer of only partial
binding activity for H6.B10 and H6.M48 binding suggests
that additional HPV 6-specific residues are required to
confer 6-specific binding for these two antibodies. The
binding results with the cross-reactive mAb H6.J54 and
the HPV 11-specific H11.B2 are similar for both mutant
and wild-type VLPs, indicating that these mutant VLPs
assemble and are not grossly distorted.
FIG. 2. HPV 6-specific mAb binding to HPV 11 VLPs bearing HPV
-like substitutions near the amino-terminus. HPV 6-specific mAbs
6.B10.5 and H6.M48 show near-quantitative binding to HPV 11 VLPs
aving three HPV 6-like amino acid substitutions at residues 49, 53,
nd 54. Monoclonal H6.N8 quantitatively binds the HPV 11 VLPs bear-
ng a single HPV 6-like residue at position 53. A 450 signals are the
averages of duplicate samples; the data are representative of assays
performed at least three times.A second region defined by L1 residues 169–178
contributes to H6.B10 and H6.M48 type-specific
binding
The analysis of binding to HPV 6 mutants (Table 2)
suggested that a second region of L1 may also play a
role in recognition by two of the antibodies. Both
H6.B10.5 and H6.M48 reacted with VLPs produced from
mutant H6:169–178 less well than with wild-type HPV 6
VLPs. To investigate whether this second site might also
be required for binding, we generated HPV 11 L1 mu-
tants with 6-like substitutions throughout this region (Ta-
ble 1, Fig. 1). These additional mutants were made in
both the HPV 11 prototype and the HPV 11:49–54 L1
mutant backgrounds. [Because HPV 11 L1 has a one-
residue insertion at position 132 relative to HPV 6 L1, the
numbering of HPV 11 residues carboxy-terminal to 132 is
shifted up by one, relative to HPV 6 L1 numbering (Fig.
1).] Antibody binding assays (Fig. 3) demonstrated that
HPV 6 residues in both the 49–54 and the 170–179
regions are necessary to confer quantitative binding for
mAbs H6.B10.5 and H6.M48. Unlike the results with the
49–54 region where HPV 6-like substitutions conferred
partial binding, no binding was detected in HPV 11 VLPs
bearing the 170–179 substitutions alone (Fig. 3). How-
ever, the requirement for this region to be “6-like” for
quantitative binding of H6.B10.5 or H6.M48 to occur in-
dicates that the region plays a fundamental role in proper
epitope presentation. The HPV 11-specific, conformation-
dependent mAb H11.B2 recognizes both prototype HPV
11 and HPV 11:49–54, 170–179 VLPs equally well, dem-
onstrating that the mutations neither grossly alter the
VLP structure nor affect the dominant HPV 11-specific
FIG. 3. HPV 6-specific mAb binding to HPV 11 VLPs having HPV
6-like substitutions in two regions. Monoclonals H6.B10.5 and H6.M48
bind quantitatively to HPV 11 VLPs bearing HPV 6-like amino acid
substitutions in the regions defined by residues 49–54 and 170–179.
A 450 signals are the averages of duplicate samples; the data are
representative of assays performed three or more times.epitope (H11.B2) that maps to residues 123–141 (Lud-
merer et al., 1996).
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265NEUTRALIZING EPITOPES OF HPV 6mAbs H6.B10.5 and H6.M48 neutralize HPV 6
infectivity with high titer
Using a novel HPV neutralization assay, Yeager et al.
(2000) demonstrated that mAbs H6.B10.5, H6.N8, and
H6.M48 specifically neutralize HPV 6 pseudovirions. To
provide more quantitative data, we have extended those
observations for H6.M48 and H6.B10.5, the monoclonals
with the more complex binding pattern. Purified IgGs
were assayed in the pseudoneutralization assay along
with IgGs from HPV-type controls H11.B2 and H16.V5 and
from mAb 6021S, a control monoclonal to hepatitis B
virus surface antigen (quantities of H6.N8 were too lim-
ited to perform titrations with purified IgG). The results
are shown in Table 3. Both HPV 6-specific monoclonals
were strongly neutralizing throughout the titration. The
HPV 11 mAb H11.B2 also shows neutralizing activity, but
with a titer that is approximately 100-fold lower than
those of the HPV 6-specific mAbs. H16.V5, which does
not bind HPV 6 or 11 VLPs, showed no neutralizing
activity for HPV 6, even at the highest concentration
tested.
DISCUSSION
These studies provide the first epitope mapping data
for antibodies that neutralize HPV 6. They have identified
two regions in the linear sequence of L1 that contribute
to type-specific, conformation-dependent, neutralizing
epitopes. Both regions occur at positions in L1 where the
sequence is highly diverged from that of HPV 11. The
region encompassing amino acid residues 49–54 ap-
pears to contain determinants of a dominant epitope for
HPV 6 since all three antibodies bind there. It is possible
that other surfaces elicit type-specific neutralizing re-
sponses and that they will be revealed by a larger set of
monoclonals. However, there is a precedent for a single
immunodominant site in HPV 11 (Ludmerer et al., 1997,
000). In that case, the majority of characterized type
TABLE 3
Neutralization of HPV 6 Pseudovirions
mAb concentration
(mg/ml)
% Inhibitiona
Monoclonal antibody
H6.B10.5 H6.M48 H11.B2 H16.V5
98.6 100.0 93.8 ,2
0.333 68.9 95.5 35.8 ,2
0.033 32.1 38.6 ,2 ,2
0.003 35.6 21.1 ,2 n.d.b
a Percentage inhibition was determined by comparing the reduction
n signals for the HPV mAbs to that for the control HBV mAb at eacht
H
ntibody concentration.
b Not determined.1-specific neutralizing mAbs derived from mice immu-
ized with HPV 11 virions recognized the same region,
he diverged sequence centered on residues 131–132. To
dentify subsidiary neutralizing epitopes, it was neces-
ary to immunize mice with VLPs in which the dominant
pitope had been disrupted (Ludmerer et al., 2000).
For mAb H6.N8, type specificity is conferred by a
ingle residue at position 53. The 49–54 region also is
ritical for recognition by mAbs H6.B10.5 and H6.M48,
ut unlike the H6.N8 case, residues 49 and 54 also
ontribute to the binding. However, even with the triple
utation (H6:49–54), which renders the HPV 11 L1 se-
uence identical to HPV 6 L1 from residue 29 through
18, the binding activities for H6.B10.5 and H6.M48 are
nly partially transferred to the HPV 11 VLP. This sug-
ested that additional HPV 6 residues are required for
ull binding activity.
This second binding region, defined by residues 169–
78, differs from the first in that (1) it is not required for
6.N8 binding and (2) no binding to this region alone
ould be demonstrated. However, a contribution to
6.B10.5 and H6.M48 epitope(s) formation or stabiliza-
ion is clearly demonstrated by the transfer of quantita-
ive binding for those mAbs to the HPV11:49–54, 170–179
LPs. Our results indicate that the N8 epitope overlaps
ut is distinct from the epitope(s) recognized by H6.B10.5
nd H6.M48. However, the data do not establish whether
10.5 and M48 epitopes are identical or not. We infer the
atter from the small reproducible differences in binding
o mutants of the 49–54 region. This would be similar to
PV 11 where neutralizing mAbs H11.B2, H11.F1, and
11.G5 all bind the same immunodominant region but
ith differences in the major contact points (Ludmerer et
l., 1996, 1997). The data indicate that B10.5 and M48
pitopes are discontinuous and comprise two sequence
egions separated in the linear sequence by more than
00 residues. The participation of two diverged se-
uence regions in neutralizing epitopes has been previ-
usly demonstrated for HPV 11. Epitopes for neutralizing
Abs H11.G131S.I1 and H11.G131S.K5 include residues
rom the diverged regions at positions 263–290 and 346–
49 (Ludmerer et al., 2000). Moreover, in mapping stud-
es of mAb H11.A3.2, a monoclonal that neutralizes virus
n an RT-PCR assay, but not in the mouse xenograft
ssay, we found that binding required both the 49–54 and
he 170–179 regions of HPV 11 (unpublished observa-
ions).
B10.5, M48, and N8 add to a growing list of monoclo-
al antibodies that define neutralizing epitopes in vari-
us HPV types. All share the property of conformational
ependence—binding only ordered structures such as
irions (Christensen and Kreider, 1990), assembled par-
icles (Christensen et al., 1996a,b), or capsomeres (Rose
t al., 1998). Most are also type-specific. For HPV 11,ype-specific monoclonal antibodies H11.F1, H11.B2,
11.G5, H11.A3.2, H11.H3, and H11.G131S.G3 (Chris-
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266 MCCLEMENTS ET AL.tensen et al., 1990; Ludmerer et al., 1996) all bind VLPs in
a conformation-dependent manner and neutralize the
virus in either mouse xenograft (Bonnez et al., 1998;
Kreider et al., 1985; White et al., 1998) or RT-PCR (Smith
et al., 1993, 1995) assays. In the HPV 16 case, conforma-
tion-dependent mAbs H16.V5 and H16.E70 neutralize
HPV 16 pseudovirions. The results of many of these
mapping studies are summarized in Fig. 4. From the
physical mapping data of these HPV 6, 11, and 16
epitopes, a pattern has emerged. There appear to be a
limited number of regions in L1 that are critical for type-
specific binding. Typically, these regions map to where
the generally well-conserved HPV L1 molecules display
the greatest sequence divergence. The importance of
these diverged regions in the formation of neutralizing
epitopes is particularly evident for the closely related
types, 6 and 11. Three of the characterized HPV 11-
specific neutralizing monoclonals, H11.F1, H11.B2, and
H11.G5, recognize a dominant epitope centered on res-
idue 132, the site where HPV 11 L1 has a single amino
acid insertion relative to that of HPV 6 (Ludmerer et al.,
1996). See Fig. 1. Monoclonals H11.H3 and H11.G131S.
G3 share binding determinants that include residues 346
to 349 (Ludmerer et al., 1996, 2000); however,
H11.G131S.G3 also binds the diverged region defined by
residues 263–290 (Ludmerer et al., 2000). This latter
region modulates binding (indicated in Fig. 4 as a
dashed arrow) of H11.H3 to the 346–349 residues, further
demonstrating the interaction of these two regions in the
formation of antibody binding sites.
FIG. 4. Map of binding regions for HPV type-specific, conformation-
ependent monoclonal antibodies. The available mapping data for
onoclonal antibodies to HPV 6, 11, and 16 are summarized on a linear
epresentation of a generalized HPV L1. Using standard protein align-
ent software (Vector NTI 5) the regions of greatest sequence diver-
ence were identified and are indicated by the ovoid shapes. All
apping data were generated by epitope transfer, except where noted
y an asterisk for H16.V5. The mAbs H11.G131.G3, H11.G131.I1, and
11.G131.K5 are abbreviated here as H11.G3, H11.I1, and H11.K5, re-
pectively. The black bars above the linear scale approximate the
ositions of polypeptide loops, predicted by the structural data of Chen
t al. (2000), to project from the folded HPV 16 L1. The bar indicated by
he dagger (†) is thought to be the L1 region that mediates capsomere
ontacts. The wavy line indicates that the carboxyl-terminus of HPV 16
1 is disordered in the structure (Chen et al., 2000).Further evidence for the role of diverged regions
comes from studies of HPV 16. White et al. (1999) have
reported that VLPs bearing an amino acid substitution at
residue 50 were not recognized by neutralizing mAbs,
including H16.V5, and had lost the ability to induce robust
antibody responses. However, loss of binding may result
not only from mutations at the binding site, but also
mutations that act at a distance by distorting the VLP
conformation. Binding transfer studies have shown that
regions encompassing residues 270–290 and 345–348
are essential for H16.V5 recognition (N.D.C., manuscript
in preparation). Since antibodies to HPV 16 from the
majority of naturally infected individuals can be com-
pletely blocked by H16.V5 in competition binding assays
(Wang et al., 1997), the fine-mapping of this epitope and
its environment in the capsid should be highly relevant to
understanding the immune response to papillomavirus
infection. The recent determination of the crystal struc-
ture of HPV 16 L1 in the context of a VLP (Chen et al.,
2000) greatly facilitates our interpretation of mapping
data. Using this structure as a framework, their align-
ments and analyses of the L1 sequences from many HPV
genotypes and variants clearly show that those regions
of greatest sequence variability lie on the outward-
facing surfaces of the particle (Fig. 4). Neutralizing
epitopes for HPV 11 have been mapped to these pro-
jecting loops (Ludmerer et al., 1997, 2000). Of particu-
lar interest are the interactions of adjacent L1 mono-
mers in the pentameric subunit of the viral capsid that
causes residues, well separated in the primary or
secondary structure of the monomer, to come into
close proximity. From our mapping data, this would
appear to be the case for loops bearing residues
49–54 and 169–178. A similar argument can be made
for HPV 11 where regions defined by residues 263–290
and 346–349 both contribute to a major neutralizing
epitope recognized by H11.G131S.G3 (Ludmerer et al.,
2000). Thus the three-dimensional structure confirms
the relevance of these diverged sequence regions as
critical determinants of type-specific, neutralizing
epitopes.
Characterization of neutralizing HPV epitopes is im-
portant not only for the study of the biology of infection
but also for the design, production, and evaluation of
HPV vaccines. As additional HPV genotypes are found to
have clinical relevance and their inclusion in vaccines is
warranted, there will be increased interest in defining
neutralizing epitopes for those types. The regions of
sequence divergence provide starting points for future
mapping studies. A thorough understanding of those
viral surfaces involved in neutralization of infectivity may
allow the rational design of simplified vaccines in which
a small set of chimeric virus-like particles can provide
protection against many HPV types.
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267NEUTRALIZING EPITOPES OF HPV 6MATERIALS AND METHODS
Generation of L1 mutants and VLP ELISAs
The L1 genes of HPV 6 and HPV 11 were cloned from
clinical isolates as previously described (Dartmann et al.,
1986; Hofmann et al., 1995; Schwarz et al., 1983) and
subcloned into pBlueScript (Stratagene, La Jolla, CA) to
generate single-stranded DNA templates for mutagene-
sis. L1 mutants were generated by site-directed mu-
tagenesis using the Sculptor in vitro mutagenesis system
(Amersham International, Little Chalfont, UK), verified by
DNA sequencing, subcloned into Baculovirus transfer
vector pVL1393 (Stratagene) for expression, and verified
by complete gene sequencing.
To express VLPs, 5 mg of transfer vector plus 0.5 mg
aculoGold DNA was transfected into approximately 2 3
06 Sf9 cells using the BaculoGold Transfection System
BD Pharmingen, San Diego, CA) according to the man-
facturer’s instructions. Five to 6 days after transfection,
he cells were harvested and disrupted by sonication.
ysates were cleared by centrifugation and were as-
ayed immediately or frozen at 270°C for subsequent
nalysis. VLP-bearing and control (mock-transfected Sf9
ells) lysates were assayed in duplicate by ELISA in
xcess antibody as described previously (Benincasa et
l., 1996) except that detection of HRP activity was with
MB (Pierce, Rockford, IL) and stopped by addition of
2SO4 and quantification was at 450 nm. Primary anti-
ody was prepared by diluting ascites fluid 105 for
H6.B10.5, H6.M48, H6.J54, H6.C6, and H11.B2 or 104 for
6.N8.
PV pseudoneutralization assay
The pseudoneutralization assay was essentially as
escribed (Yeager et al., 2000). Briefly, human cervical
arcinoma C33A cells were seeded into 96-well plates
nd cultured for 2 days at 37°C before infection. Mono-
lonal antibody IgG was diluted into OPTI-MEM medium
Gibco) containing 2% normal human serum; HPV 6
seudovirions coupled to a BLAM reporter gene were
iluted to 200 ng/ml in the same medium. Culture me-
ium was removed from the C33A cells, and 25 ml of
iluted mAb was added to each well prior to the addition
f 25 ml diluted pseudovirions. Cells were grown over-
night at 37°C and then refed with 100 ml of complete
DMEM. After an additional 24 h of growth at 37°C, the
medium was removed and cells were washed with 100
ml of OPTI-MEM. Intracellular BLAM activity was quan-
tified as described previously (Yeager et al., 2000). Fluo-
rescence readings at 460 nm were obtained using a
Cytofluor (PerSeptive Biosystems, Framingham, MA)
multiwell plate reader. Triplicate wells were analyzed for
each test condition. The percentage of neutralization for
a given dilution of mAb sample was calculated from the
fluorescence signals asS1 2 ~test mAb 2 background!~control mAb 2 background!D 3 100,
where “background” is the average fluorescence signal
in wells that did not receive pseudovirions. The calcula-
tions were done for matched concentrations of test and
control mAbs. The monoclonal antibodies used in this
assay were purified from hybridoma tissue culture me-
dium by Protein A or Protein G chromatography. The
control mAb is against hepatitis B virus surface antigen
(BD Pharmingen).
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